{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:52:02Z","timestamp":1791568322531,"version":"4.3.4"},"reference-count":48,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["U01CA257638-01"],"award-info":[{"award-number":["U01CA257638-01"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is the most commonly diagnosed cancer in men worldwide. A rising proportion of men present with de novo metastatic disease, a state associated with poor survival outcomes and limited curative treatment options. Within this group, a subset of patients exhibit oligometastatic disease, defined by a limited number of metastases, which may represent a distinct clinical entity with potential for long-term disease control. Emerging evidence suggests that metastasis-directed radiotherapy (MDRT), including stereotactic body radiation therapy (SBRT), may improve progression-free survival in this population. However, current evidence is largely limited to phase II trials in the metachronous setting and retrospective studies in the synchronous setting. Furthermore, predictive biomarkers of treatment response in these patients remain undefined. We aim to evaluate, within a large randomised multicentre phase II trial, the efficacy and biological impact of MDRT in men with de novo oligometastatic PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Patients with de novo oligometastatic hormone-sensitive prostate cancer (omHSPC), defined as up to 10 sites of metastatic disease by prostate-specific membrane antigen (PSMA) positron emission tomography (PET)\/CT or up to five sites of metastatic disease by conventional imaging, are randomised (1:1) to standard of care (SOC) or SOC plus MDRT. SOC includes 12 months of androgen deprivation therapy plus an androgen receptor pathway inhibitor, with definitive treatment to the prostate by radiotherapy (RT). A predefined subset is allowed to undergo radical prostatectomy if clinically appropriate. MDRT involves SBRT to all metastatic sites identified on conventional imaging or PSMA PET\/CT. Target enrolment is 200 patients, stratified by diagnostic imaging modality, number of bone metastases, plan to MDRT all sites of metastases and local therapy approach.<\/jats:p>\n                    <jats:p>Prostate RT may be delivered using moderate (20 fractions) or ultra-hypofractionation (five fractions), with optional simultaneous-integrated-boost to dominant intraprostatic lesions. MDRT regimens aim for a biologically effective dose \u2265100\u2009Gy (\u03b1\/\u03b2=1.5) using 1\u20135\u2009fractions. Gross tumour volumes are delineated based on MRI, CT and PSMA PET\/CT.<\/jats:p>\n                    <jats:p>\n                      The primary endpoint is failure-free survival, defined using cause-specific PCa death. The study is powered at 80% to detect a HR of 0.58 using a one-sided alpha of 0.05. Secondary endpoints include radiographic progression-free survival, overall survival (OS), time to next intervention, time to castration-resistant PCa, PCa-specific mortality and patient-reported outcomes. Biospecimen collection and imaging data will support future translational analyses. Data from this trial is preplanned to be pooled with the STAMPEDE 2 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06320067\">NCT06320067<\/jats:ext-link>\n                      ) trial, a phase III randomised trial to assess OS benefit of MDRT in men with de novo omHSPC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This clinical trial is approved by the Case Comprehensive Cancer Center Institutional Review Board (STUDY20231440). The results will be disseminated via peer-reviewed scientific journals and conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06150417\">NCT06150417<\/jats:ext-link>\n                      (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06150417\">https:\/\/clinicaltrials.gov\/study\/NCT06150417<\/jats:ext-link>\n                      )\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-116331","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:09:54Z","timestamp":1791565794000},"page":"e116331","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06320067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06150417","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06320067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02772588","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03298087","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-9409","authenticated-orcid":false,"given":"Samuel","family":"Lichtman-Mikol","sequence":"first","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M","family":"Lang","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Nagar","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Zuhour","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin V","family":"Chaung","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G","family":"Zaorsky","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyajit","family":"Roy","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek M","family":"Mendiratta","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E","family":"Shoag","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-4852","authenticated-orcid":false,"given":"James R","family":"Janopaul-Naylor","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Khani","sequence":"additional","affiliation":[{"name":"NewYork-Presbyterian Weill Cornell Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M","family":"Schaeffer","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos E","family":"Kyriakopoulos","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Barata","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R","family":"Brown","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A","family":"Garcia","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E","family":"Barbieri","sequence":"additional","affiliation":[{"name":"NewYork-Presbyterian Weill Cornell Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1341-382X","authenticated-orcid":false,"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L","family":"Choyke","sequence":"additional","affiliation":[{"name":"National Institutes of Health National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E","family":"Spratt","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-2614","authenticated-orcid":false,"given":"Angela Y","family":"Jia","sequence":"additional","affiliation":[{"name":"UH Seidman Cancer Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2026100606201118000_16.10.e116331.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2026100606201118000_16.10.e116331.2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026100606201118000_16.10.e116331.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70028"},{"key":"2026100606201118000_16.10.e116331.4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026100606201118000_16.10.e116331.5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","article-title":"Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States","volume":"4","author":"Kelly","year":"2018","journal-title":"Eur Urol Focus"},{"key":"2026100606201118000_16.10.e116331.6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0052"},{"key":"2026100606201118000_16.10.e116331.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3"},{"key":"2026100606201118000_16.10.e116331.8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026100606201118000_16.10.e116331.9","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"2026100606201118000_16.10.e116331.10","doi-asserted-by":"publisher","DOI":"10.1038\/nature14347"},{"key":"2026100606201118000_16.10.e116331.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"2026100606201118000_16.10.e116331.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"2026100606201118000_16.10.e116331.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900"},{"key":"2026100606201118000_16.10.e116331.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"2026100606201118000_16.10.e116331.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01798"},{"key":"2026100606201118000_16.10.e116331.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2026100606201118000_16.10.e116331.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.075"},{"key":"2026100606201118000_16.10.e116331.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.10.008"},{"key":"2026100606201118000_16.10.e116331.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03828-2"},{"key":"2026100606201118000_16.10.e116331.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8"},{"key":"2026100606201118000_16.10.e116331.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30415-2"},{"key":"2026100606201118000_16.10.e116331.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00201"},{"key":"2026100606201118000_16.10.e116331.23","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomised Clinical Trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026100606201118000_16.10.e116331.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5"},{"key":"2026100606201118000_16.10.e116331.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.02.031"},{"key":"2026100606201118000_16.10.e116331.26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomised Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026100606201118000_16.10.e116331.27","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","article-title":"Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer","volume":"43","author":"Pyka","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100606201118000_16.10.e116331.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5791"},{"key":"2026100606201118000_16.10.e116331.29","first-page":"1765","article-title":"A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index","volume":"4","author":"Imbriaco","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2026100606201118000_16.10.e116331.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.11.036"},{"key":"2026100606201118000_16.10.e116331.31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.27_suppl.42"},{"key":"2026100606201118000_16.10.e116331.32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.2020.38.6_suppl.153","article-title":"Multiregion expression profiling of prostate cancer from men randomised in the STAMPEDE trial: Stage I results of a multistage biomarker analysis","volume":"38","author":"Grist","year":"2020","journal-title":"JCO"},{"key":"2026100606201118000_16.10.e116331.33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1200\/JCO.2020.38.6_suppl.162","article-title":"Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED","volume":"38","author":"Hamid","year":"2020","journal-title":"JCO"},{"key":"2026100606201118000_16.10.e116331.34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026100606201118000_16.10.e116331.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.08.034"},{"key":"2026100606201118000_16.10.e116331.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.052"},{"key":"2026100606201118000_16.10.e116331.37","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardised reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100606201118000_16.10.e116331.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008"},{"key":"2026100606201118000_16.10.e116331.39","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2021.39.15_suppl.5012","article-title":"Interim results of aasur: A single arm, multi-centre phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA+P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)","volume":"39","author":"McBride","year":"2021","journal-title":"JCO"},{"key":"2026100606201118000_16.10.e116331.40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","article-title":"Systemic and Tumour-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer","volume":"86","author":"Nickols","year":"2024","journal-title":"Eur Urol"},{"key":"2026100606201118000_16.10.e116331.41","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.ijrobp.2012.03.009","article-title":"International Spine Radiosurgery Consortium Consensus Guidelines for Target Volume Definition in Spinal Stereotactic Radiosurgery","volume":"83","author":"Cox","year":"2012","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2026100606201118000_16.10.e116331.42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/COC.0000000000000635","article-title":"Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence","volume":"43","author":"Viani","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"2026100606201118000_16.10.e116331.43","doi-asserted-by":"publisher","DOI":"10.1118\/1.3438081"},{"key":"2026100606201118000_16.10.e116331.44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin Oncol"},{"key":"2026100606201118000_16.10.e116331.45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijrobp.2019.09.038","article-title":"Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy","volume":"110","author":"Sahgal","year":"2021","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2026100606201118000_16.10.e116331.46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00644"},{"key":"2026100606201118000_16.10.e116331.47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomised Clinical Trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026100606201118000_16.10.e116331.48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(25)00658-8","article-title":"Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration","volume":"27","author":"Tang","year":"2026","journal-title":"Lancet Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-116331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:09:58Z","timestamp":1791565798000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-116331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,6]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjopen-2026-116331"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-116331","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}